In Vitro Evaluation of A-56619 and A-56620, Two New Quinolones.

Antimicrobial Agents and Chemotherapy - United States
doi 10.1128/aac.29.1.40
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society for Microbiology

Related search

In Vitro Evaluation of A-56619 (Difloxacin) and A-56620: New Aryl-Fluoroquinolones.

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
1986English

Therapeutic Evaluation of Difloxacin (A-56619) and A-56620 for Experimentally Induced Bacteroides Fragilis-Associated Intra-Abdominal Abscess.

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
1986English

Comparative In-Vitro Activity of New Quinolones Against Clinical Isolates and Resistant Mutants

Journal of Antimicrobial Chemotherapy
Infectious DiseasesMicrobiologyPharmacology
1992English

Clinical and in Vitro Evaluation of Cephapirin, a New Cephalosporin Antibiotic

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
1972English

In Vitro Activities of Gatifloxacin, Two Other Quinolones, and Five Nonquinolone Antimicrobials Against Obligately Anaerobic Bacteria

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
1999English

Anti-Mycobacterium Avium Activity of Quinolones: In Vitro Activities.

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
1993English

Biological and Antibacterial Properties of a New Silver Fiber Post: In Vitro Evaluation

Journal of Clinical and Experimental Dentistry
Dentistry
2017English

In Vitro Evaluation of a New Aminoglycoside Derivative of Kanamycin, a Comparison With Tobramycin and Gentamycin

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
1973English

In Vitro Evaluation of E1040, a New Cephalosporin With Potent Antipseudomonal Activity.

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
1988English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy